SCHEMBL3076371

SCHEMBL3076371

O=[C]N1CCN(c2ccccc2)CC1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD4 P21917 1/20 0.52
ALDH1A1 P00352 4/20 0.48
MEN1 O00255 1/20 0.48
USP2 O75604 1/20 0.48
TSHR P16473 1/20 0.48
KMT2A Q03164 1/20 0.48
LMNA P02545 3/20 0.48
MAPT P10636 3/20 0.48
CHRNA7 P36544 2/20 0.48
SIGMAR1 Q99720 2/20 0.48
HTR3E A5X5Y0 1/20 0.48
HTR3B O95264 1/20 0.48
ADRB1 P08588 1/20 0.48
HTR3A P46098 1/20 0.48
HTR3D Q70Z44 1/20 0.48
HTR3C Q8WXA8 1/20 0.48
MAPK1 P28482 2/20 0.47
KCNH2 Q12809 1/20 0.47
NPSR1 Q6W5P4 1/20 0.46
CYP2C9 P11712 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8717874 0.81 HTR3E (0.53) DRD4ALDH1A1MEN1KMT2ALMNA
SCHEMBL385012 0.81
SCHEMBL16924853 0.81 LMNA (0.67) DRD4ALDH1A1MEN1USP2TSHR
SCHEMBL576454 0.81 LMNA (0.67) DRD4ALDH1A1MEN1USP2TSHR
SCHEMBL164538 0.81 LMNA (0.67) DRD4ALDH1A1MEN1USP2TSHR
SCHEMBL576814 0.81 LMNA (0.67) DRD4ALDH1A1MEN1USP2TSHR
SCHEMBL8984715 0.79 ADRB1 (0.52) ALDH1A1MEN1KMT2ALMNAMAPT
SCHEMBL298843 0.79 MAPT (0.57) ALDH1A1USP2TSHRLMNAMAPT
SCHEMBL2383844 0.79 CHKA (0.57) ALDH1A1TSHRMAPTCYP2C9CYP2C19
SCHEMBL1462575 0.78 USP30 (0.51) DRD4ALDH1A1MEN1USP2TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060281725-A1 Agents and crystals for improving excretory potency of urinary bladder ISIHARA YUJI 2006-12-14 US claimed
EP-1604653-A1 Acetylcholinesterase inhibitors for improving excretory potency of urinary bladder Takeda Pharmaceutical Company Limited (JP) 2005-12-14 EP claimed
CN-1572299-A Medicine for improving excretion capacity of bladder TAKEDA CHEMICAL INDUSTRIES LTD (JP) 2005-02-02 CN claimed
US-20040116457-A1 Agents for improving excretory potency of urinary bladder TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2004-06-17 US claimed
US-20040063699-A1 Gpr14 antagonist TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2004-04-01 US claimed
EP-1310490-A1 GPR14 ANTAGONIST Takeda Chemical Industries, Ltd. (JP) 2003-05-14 EP claimed
JP-2002542245-A 2002-12-10 JP claimed
US-20020177593-A1 Agents and crystals for improving excretory potency of urinary bladder TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2002-11-28 US claimed
EP-1173438-A1 SUBSTITUTED IMIDAZOLES, THEIR PREPARATION AND USE NOVO NORDISK A/S (DK) 2002-01-23 EP claimed
CN-1328451-A Medicine for improving excretion capacity of bladder TAKEDA CHEMICAL INDUSTRIES LTD (JP) 2001-12-26 CN claimed
EP-1118322-A1 DRUGS FOR IMPROVING VESICAL EXCRETORY STRENGTH Takeda Chemical Industries, Ltd. (JP) 2001-07-25 EP claimed
WO-2000063208-B1 SUBSTITUTED IMIDAZOLES, THEIR PREPARATION AND USE NOVO NORDISK AS (DK) 2000-12-14 WO claimed
WO-2000063208-A1 SUBSTITUTED IMIDAZOLES, THEIR PREPARATION AND USE NOVO NORDISK A/S (DK) 2000-10-26 WO claimed
US-5776936-A Marcfortine/paraherquamide derivatives useful as antiparasitic agents PHARMACIA & UPJOHN COMPANY (US) 1998-07-07 US claimed
US-5677283-A α-heteroaryloxymethyl ketones as interleukin - 1 β converting enzyme inhibitors SANOFI (FR) 1997-10-14 US claimed
US-5290807-A Antiinflammatory agents CHILDREN'S MEDICAL CENTER CORPORATION (US) 1994-03-01 US claimed
US-4971957-A ANTILIPEMIC AGENTS, ANTICHOLESTEROL AGENTS, BENZENECARBOXAMIDOPHOSPHONATES OR BENZENETHIOCARBOXAMIDOPHOSPHONATES OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) 1990-11-20 US claimed
EP-0226636-B1 NEW CARBOXYLIC ACID DERIVATIVES, THEIR MANUFACTURING PROCESS, USE AND MEDICINES CONTAINING THESE COMPOUNDS Roche Diagnostics GmbH (DE) 1989-02-08 EP claimed
US-4716162-A BRAIN FUNCTION SANKYO COMPANY, LIMITED (JP) 1987-12-29 US claimed
US-3960858-A 3-Hetero acyl-2,3-benzoxazepines GRUPPO LEPETIT S.P.A. (IT) 1976-06-01 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020177593-A1 Agents and crystals for improving excretory potency of urinary bladder ACHE, BPHL, BCHE DRD4 3841/4885ALDH1A1 1185/4885MEN1 3760/4885
US-20060281725-A1 Agents and crystals for improving excretory potency of urinary bladder ACHE, BCHE, PDE7A DRD4 3292/4885ALDH1A1 1245/4885MEN1 3303/4885
US-20040063699-A1 Gpr14 antagonist GPR142, GPR139, GPR4 DRD4 857/4885ALDH1A1 2561/4885MEN1 3436/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.